Immune Evasion by Herpes Simplex Viruses by Retamal-Díaz, Angello R. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Immune Evasion by Herpes Simplex Viruses
Angello R. Retamal-Díaz, Eduardo Tognarelli,
Alexis M. Kalergis, Susan M. Bueno and
Pablo A. González
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64128
Abstract
Infection with herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) is extremely
frequent in the human population, as well as recurrent reactivations due to lifelong
infection. Infection and persistence of HSVs within healthy individuals likely results as
a consequence of numerous molecular determinants evolved by these pathogens to
escape both immediate and long-term host antiviral mechanisms. Indeed, HSVs harbor
an arsenal  of  proteins that  confer  them stealth by negatively modulating immune
function. Consequently, these viruses perpetuate within the host, altogether silently
shedding onto other individuals. In this chapter, we discuss HSV determinants that
interfere with cellular antiviral factors, as well as viral determinants that hamper innate
and adaptive immune components intended to control such microbes. The identifica‐
tion of  HSV evasion molecules  that  modulate  the  immune system,  as  well  as  the
understanding of their mechanisms of action,  should facilitate the design of novel
prophylactic and therapeutic strategies to overcome infection and disease elicited by
these viruses. This chapter is intended to provide an overview of the evasion mecha‐
nisms evolved by herpes simplex viruses to escape numerous host antiviral mediators.
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1. Introduction
Herpes simplex viruses (HSVs, HSV-1 and HSV-2) are extremely prevalent in the human
population with virtually half of the world inhabitants infected with HSV-1 [1] and nearly 500
million with HSV-2 [2]. Novel infections with HSVs are estimated at a rate of dozens of millions
individuals per year [3]. Importantly, the prevalence of HSV infection significantly varies
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depending on the geographical location of individuals, sex, and ethnicity [3–7]. While pri‐
mary HSV-1 infection is well known for its pathological effects in the oro-facial area, where it
mainly produces lesions in the mouth, it is also responsible for most cases of infectious blindness
in developed countries [8–21]. On the other hand, HSV-2 is widely recognized as an impor‐
tant contributor to neonatal encephalitis and, most importantly, the main cause of genital ulcers
in the world [8–21]. Nevertheless, despite this latter association between HSV-2 and genital
infection, HSV-1 is at present the main cause of primary genital infection [9, 12]. This appa‐
rent paradox may be explained by the fact that HSV-2 recurs significantly more frequently in
the genitalia than HSV-1, while the opposite occurs for the oro-facial area [22]. Such differen‐
ces may be accounted by disparities in the capacity of each of these viruses to establish latency
in the sacral and trigeminal ganglia [23], although another study proposes that this is not the
case [24]. Regardless of differences in neuron infection or reactivation capacity from these sites,
overall HSV-2 is isolated more frequently than HSV-1 in the genitalia during the lifespan of an
individual [23]. Importantly, HSV-2 is considered at present a meaningful contributor to the
fueling of human immunodeficiency virus (HIV) infection in the world, and is discussed in
detail below [22, 25–27].
Besides viral encephalitis in neonates, as well as oro-facial and genital lesions, HSV-1 and
HSV-2 are also responsible for numerous other diseases in humans, such as adult encephalitis,
herpetic keratitis, conjunctivitis, and skin lesions, within many other clinical manifestations [4].
The variety of pathologies produced by HSVs and tissues affected may be due, at least partially,
to the wide distribution of their receptors, which are virtually present on all cells of the body
[28]. Noteworthy, such clinical outcomes can occur indistinguishably both in immunocompe‐
tent and immunocompromised individuals and are likely a result of the evolution and selection
of HSV determinants that interfere with early antiviral cellular mechanisms, innate- and
adaptive-immune components. Noteworthy, HSV genomes encode numerous gene products
(at least 70), which likely warrants these microbes a collection of proteins with immune evasion
properties [29]. Below, we discuss several of these viral determinants, as well as how they
interfere with host antiviral processes.
2. Herpes simplex viruses escape early antiviral responses
2.1. Interference with host pathogen recognition receptors
Upon encounter with foreign molecules or danger elements, host immune and nonimmune
cells may sense such stimuli and initiate intracellular-activating signaling pathways that lead
to their alertness and that of surrounding cells. Importantly, complex host organisms have
evolved as specialized receptors for recognizing these microbial elements or self-induced
danger molecules during abnormal processes elicited by these microbes. Such receptors are
usually termed pattern recognition receptors (PRRs) [30]. PRRs can recognize pathogen-
associated molecular patterns (PAMPs), which consist on a diverse collection of biomolecules
derived from microbial elements, such as proteins, lipids, carbohydrates, or particular
arrangements or sequences of nucleic acids, within others [31]. Alternatively, these receptors
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can also detect danger signals released by host cells undergoing stress circumstances, such as
those that might be elicited by virus replication. These latter danger signals are termed
damage-associated molecular patterns (DAMPs) [32]. Upon engaging PAMPs and DAMPs,
PRRs elicit intracellular signals that result in the transcription and translation of antiviral
genes, as well as the expression of soluble and membrane-bound molecules. Timely and robust
detection of PAMPs and DAMPs by the host after viral infection can lead to effective microbe
control and promote the establishment of protective immunity [31, 33].
Upon exposure to HSVs, the main host cells susceptible to infection are likely live epithelial
cells. These cells are largely present at the interphase with the exterior world and abundantly
present in the mucosae and to a lesser extent, in microscopic skin lesions. As most nonimmune
cells in the organism, these cells express the main HSV receptor, nectin-1 [28]. After attaching
and binding to their receptors, the membranes of these viruses undergo a fusion process with
that of the host cell to release the viral capsid and surrounding tegument proteins within the
cytoplasm [34]. While the tegument proteins remain in the cytoplasm, where they exert
numerous cellular modulatory effects, the capsid associates to microtubules and travels to the
outer nuclear membrane, where it binds to host nuclear pore proteins and releases the viral
DNA into the nucleus [35]. It has been described that at this stage host molecular sensors can
sense HSV-2 determinants (Table 1). Interferon-gamma inducible-16 (IFI-16) detects the HSV
genome and subsequently induce IL-6 and IFN-α production in primary vaginal epithelial
cells [36–38]. On the other hand, the cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) synthase (cGAS), a recently described DNA sensor, has also been
reported to detect HSV-derived nucleic acids and lead to IFN-α and IFN-β secretion by both
immune cells, such as macrophages and dendritic cells (DCs), and nonimmune cells, such as
fibroblasts [39]. Importantly, animals that lack cGAS are vulnerable to HSV, while functional
cGAS leads to T-cell activation and antibody production by B cells [40]. Although HSVs seem
to be unable to interfere with cGAS sensing, other herpesviruses (gammaherpesviruses) have
been recently described to encode viral determinants that impair the function of this molecule,
namely, ORF52 of Kaposi’s sarcoma herpesvirus [41]. Interestingly, a recent study suggests
that IFI16 and cGAS work cooperatively to sense HSV, as silencing one or both proteins
significantly decreases virus detection. More specifically, cGAS was shown to directly interact
with IFI-16 in fibroblasts and to promote the stability of the latter [39]. Noteworthy, both
sensors IFI-16 and cGAS signal intracellularly through interferon regulatory factor-3 (IRF3)
and again silencing either sensor inhibits the activation of IRF3 in response to HSV DNA [42].
Further, the importance of IFI-16 in limiting HSV infection has been recently shown in vivo.
Knocking down IFI-16 led to the loss of IFN-α production, as well as reduced viral control in
the corneal epithelium [38]. While the mechanism by which IFI-16 recognizes HSV DNA
remains somewhat unclear, a recent study using chromatin immunoprecipitation (ChIP) found
that IFI-16 binds to HSV promoter sequences and that reducing the levels of IFI-16 expression
resulted in host proteins binding to these elements, ultimately favoring viral gene transcription
[43].
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Host
sensor
Viral determinant involved Outcome Mechanism References
IFI-16 Nuclear virus DNA HSV sensed. IL-6, IFN-α
secretion
IFI-16 binds to viral promoters [36–38, 43]
cGAS Nuclear virus DNA HSV sensed. IFN-α, IFN-β
secretion
cGAS binds directly to B-DNA [39]
DAI Cytosolic virus DNA HSV sensed. IL-6, IFN-β
secretion
DAI binds directly to B-DNA [36]
MDA5 vhs Unable to sense viral nucleic
acids
vhs protein reduces host
protein expression
[44, 45]
RIG-1 vhs Unable to sense viral nucleic
acids
vhs protein reduces host
protein expression
[44, 45]
TLR-9 Cytosolic virus DNA HSV sensed. IL-6, IL-12, type-I
IFN secretion
Undetermined [36, 46]
PKR γ34.5 and US11 Impaired viral dsRNA
recognition
Viral proteins block eIF2-α
phosphorylation
[53–57]
TLR7 Undetermined HSV sensed Undetermined [58]
TLR3 Virus or virus-induced
host nucleic acids
HSV sensed. IL-6, TNF-α
secretion
TLR-3 signals through IRF3 [63–65]
ανβ3 ICP0 Inhibited detection of viral
proteins
ICP0 blocks type-I IFN
transcription and virus targeting
to degradation
[74–76]
TLR2 dUTPase HSV sensed. IL-6, IL-8, IL-10,
IL-12, and TNF-α secretion
Undetermined [77]
Inflamm– 
asome
ICP0 ICP0 reduces IL-1β secretion Inflammasome directed to
proteasome degradation in
timely manner
[32, 43]
IFI-16 (gamma-interferon-inducible protein); cGAS (cyclic GMP-AMP synthase); DAI (DNA-dependent activator of
Interferon-regulatory factor); MDA5 (melanoma differentiation-associated protein 5); vhs (virion host shutoff protein);
RIG-1 (retinoic acid-inducible gene 1); TLR-2, -7, -9 (Toll-like receptor-2, -7 and -9); PKR (protein kinase RNA-
activated); ανβ3 (integrin alphaVbeta3); γ34.5 (late gene gamma 34.5, ICP34.5); US11 (short unique region 11); IRF3
(interferon regulatory factor 3); ICP0 (infected cell protein 0); IL-1β, -6, -8, -10,-12 (interleukin-1β, -6, -8, -10, and, -12);
IFN-α/β (interferon alpha and beta); TNF-α (tumor necrosis factor-alpha).
Table 1. HSV evasion of host virus sensing.
Another host DNA sensor capable of detecting HSV genetic material is DNA-dependent
activator of interferon (DAI), which is expressed in primary vaginal epithelial cells and leads
to cytokine expression by these cells, such as IL-6 and IFN-β after virus exposure (Table 1) [36].
Surprisingly, DAI is expressed in the cytoplasm, suggesting that HSV DNA likely escapes or
leaks from the nucleus, or capsids into the cytoplasm where it reaches this sensor.
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Other nucleic acid detectors intended to perceive microbe-derived genetic material are retinoic
acid-inducible gene-1 (RIG-I) and melanoma differentiation-associated protein-5 (MDA5)
(Table 1) [44]. Unlike the other DNA sensors discussed above, the functions of RIG-I and
MDA5 are hampered by HSV, namely, by the viral protein designated virion host shutoff
protein (vhs). The vhs has been shown to specifically reduce the expression RIG-I and MDA5,
as a mechanism to interfere with downstream signaling events carried out by these detectors,
which are intended to alert neighboring and immune cells when viral elements are present
(Table 1) [45]. Similar to DAI, RIG-I and MDA5 are also present in the cytoplasm of cells, which
indicates that HSV DNA likely reaches this compartment during the infectious cycle [36].
Another PRR that also recognizes viral DNA is Toll-like receptor-9 (TLR9), which is mainly
known for its role in sensing bacterial-derived nucleic acids, namely, CpG-oligodeoxynucleo‐
tides (CpG ODNs). TLR9, which is expressed both by immune and nonimmune cells, has been
shown to detect HSV elements and produce IL-6, IL-12, and type-I IFN, within others (Table
1) [36, 46]. Although TLR9 is capable of sensing HSV, its function seems nonessential for animal
survival upon viral challenge. Indeed, TLR9 knockout mice survive central nervous system
(CNS) infection, although they do display increased viral loads in the brain, when compared
to wild-type mice [47]. Remarkably, animals treated with TLR9 agonists, such as CpG ODNs
previous to infection, display significantly reduced viral loads and inflammatory cytokines in
the brain (CCL2, IL-6, and CCL5) [48]. A similar protective effect has been observed for CpG
ODNs in mice that were treated locally with such stimulators and then challenged in the
genitalia with HSV [49–52]. These results suggest that engaging TLR9 receptors, or promoting
their signaling pathways may be a promising strategy for preventing HSV burden in the host.
Although the genomes of HSVs are composed of DNA, these viruses produce viral RNA
molecules during their infectious cycles that are generated as a consequence of transcription.
These RNA molecules are then processed into mRNAs and miRNAs that may form tridimen‐
sional structures, which could be recognized by host sensors. One such sensor is host protein
kinase R (PKR), which can detect double-stranded RNA molecules and mediate downstream
signaling events that lead to limited virus replication by favoring NF-kB activation and
cytokine release, while altogether inhibiting protein synthesis through the phosphorylation of
the host translation initiation factor 2-alpha (eIF2α), which ultimately can promote cell death
(apoptosis) [53]. To date, numerous studies have demonstrated that HSV can indeed interfere
with PKR function both in vitro and in vivo in such a way to promote their infectious cycles
(Table 1) [54, 55]. Furthermore, interference with the capacity of PKR to phosphorylate
eIF2α has been shown to be mediated by the HSV proteins γ34.5 and US11, which allows viral
protein synthesis to occur efficiently within infected cells [56, 57].
Another nucleic acid-sensing molecule capable of recognizing double-stranded RNA species
produced during viral infection is TLR7, although to date this particular receptor has not been
described to sense any particular form of nucleic acid generated during HSV infection (Table
1). Nevertheless, some studies report that the application of TLR7 agonists, such as imiquimod
to experimental animals can significantly decrease HSV infection and disease after virus
challenge [58]. Such findings have led to the assessment of imiquimod as a therapeutic
approach to treat HSV infection in humans, particularly for combating HSV isolates that are
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resistant to acyclovir, which are commonly found in immunocompromised patients [59–61].
For example, a recent report described successful treatment of hypertrophic genital herpes in
a HIV-positive patient after using 5% imiquimod applied in a topical manner after repeated
failure to resolve the symptoms in the patient with oral and intravenous antivirals [62].
Although the results obtained till date on this type of approach have been promising, the
mechanism of action of imiquimod over HSV remains unclear, as both interferon-dependent
and interferon-independent mechanisms seem to play favorable roles against viral infection,
which may further be mediated by processes that are independent of TLR engagement [60].
Lastly, another host nucleic acid sensor is TLR3, which is mainly known to recognize double-
stranded RNA [63]. Importantly, TLR3 has been reported to play relevant roles in HSV disease,
although its participation during infection has mainly been inferred by its deficiency (Table
1). For instance, TLR3−/− mice display severe HSV burden within the CNS after infection, which
is thought to be mediated by astrocyte infection. Indeed, the expression of TLR3 in such cells
increases the control of HSV infection early after virus entry into the CNS, seemingly by
inducing type-I IFN responses [64]. Such interferon response would be mediated by TLR3-
induced NF-kB activation in astrocytes and a posterior increase in the expression of IL-6 and
TNF-α, which likely play antiviral functions in this tissue [65]. A relevant role for TLR3 in
humans was initially proposed for infants, but has now extended onto adults thanks to recent
studies performed on individuals that carry mutations in this receptor that negatively
modulate its function. For instance, individuals harboring mutations in TLR3 have been
reported to display a history of HSV encephalitis [66–69]. Additionally, a direct relationship
between downstream TLR3 signaling, TLR3 defects, and virus burden in astrocytes has been
shown with ex vivo differentiated neurons, astrocytes, and oligodendrocytes obtained from
patients that display TLR3 deficiencies. Cell cultures derived from these individuals and
infected with HSV show reduced virus control in vitro, as compared to cells obtained from
controls, which secreted more interferon [70]. Furthermore, HSV-susceptible individuals have
also been reported to display mutations in proteins that are involved in the downstream
signaling of TLR3, such as in IRF3 [69, 71, 72]. As with TLR9 and TLR7, agonists for TLR3 such
as polyI:C have also been shown to reduce viral burden when applied in the genitalia or
intraperitoneally previous to a genital challenge with HSV [73]. Overall, these results highlight
an important role for TLR3 in HSV encephalitis, altogether proposing potential new treatment
alternatives for reducing HSV burden in the brain and other tissues.
While HSV-derived nucleic acids are perceived by numerous host sensors in infected cells,
relatively few HSV proteins have been described to be detected by the host (Table 1). Integrin
ανβ3, which has seldom been recognized as a PRR was recently described as a sensor for HSV,
which is negatively modulated by these viruses. Furthermore, the HSV protein ICP0 has been
proposed to be responsible for blocking the signaling events triggered by integrin ανβ3 within
infected cells, which otherwise would lead to NF-kB activation, type-I IFN transcription, and
the direction of virus particles to cholesterol-rich microdomains that are targeted for degra‐
dation [74–76].
An HSV protein that is successfully detected by host sensors is the viral dUTPase, which has
been shown to be sensed by TLR2 in DCs and leads to IL-6, IL-8, IL-10, IL-12, and TNF-α
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secretion (Table 1) [77]. Interestingly, TLR2 has also been reported to recognize other HSV
elements, with partial modulation by TLR9 [78]. Noteworthy, experiments performed with
TLR2−/− knockout mice showed that these animals displayed increased survival rates, as
compared to wild-type animals after challenge with HSV, which suggests a potentially
negative role for this receptor in disease severity. Yet the knockout animals had similar levels
of viral loads in their tissues, as control animals [79]. Remarkably, microglia cells obtained
from TLR2−/− mice have been shown to produce reduced levels of reactive oxygen species (ROS)
after HSV infection, when compared to control cultures, which might result in decreased
cellular oxidative toxicity to neurons and positively impact on their viability [80].
The inflammasome is a host multiprotein complex harboring the cytoplasmatic sensors
NLRP3, AIM2, and IFI-16, which has been described to sense HSV constituents, although its
activation is negatively modulated during infection (Table 1) [32]. While IFI-16 and NLRP3
are activated early after HSV infection with consequent IL-1β release, at later time points IFI-16
has been reported to be directed to the proteasome by the viral protein ICP0 [32, 43]. This
observation implies that the overall function of this sensor complex is likely hampered by HSV
and thus limited at properly alerting other cells of an ongoing viral infection.
Taken together, HSVs seem to be sensed by host cells mainly at the nucleic acid level rather
than protein level. This observation is quite surprising considering that HSVs encode numer‐
ous gene products within their genomes (>70 ORFs) and at least 11 surface glycoproteins. This
stealth attribute might be explained within others by the ability of these viruses to interfere
with downstream signaling events mediated by PRRs, as discussed in detail below. Addition‐
ally, their apparent invisibility might also be a consequence of the viruses’ capacity to interfere
with host translation of mRNA transcripts that encode soluble and membrane-bound media‐
tors required for cell alertness after infection and also communicating infection onto other cells.
Indeed, the HSV-1 and HSV-2 vhs proteins efficiently inhibit the translation of host mRNAs
by promoting their degradation directly through their ribonuclease activity [81]. Importantly,
increased degradation of host transcripts over viral mRNAs would be mediated by the spatial-
temporal regulation of vhs expression in infected cells, as vhs proteins are delivered together
with the tegument immediately after infection, then poorly expressed during viral replication
and then abundantly produced immediately before virus packaging and exit [82]. More
recently, vhs proteins have been reported to interfere with stress granule formation within
infected cells, thus counteracting host antiviral stress responses that are usually elicited early
after infection [83].
2.2. Negative modulation of interferon pathways
An effective mechanism by which host cells restrict viral replication is due to interferons,
soluble proteins, that induce antiviral responses both in cells that secrete these mediators as
well as neighboring cells [84]. While type-I interferons (IFN-α, IFN-β, and IFN-ε, within others)
are usually secreted early after microbe infection by diverse cell types, type-II interferons (IFN-
γ) are secreted by specific subsets of immune cells at later stages of infection. On the other
hand, type-III interferons (IFN-λ1, IFN-λ2, and IFN-λ3) have similar effects and kinetics than
type-I IFNs, although they are mostly restricted to epithelial cells [63, 85–89]. While type-I and
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type-III IFNs induce multiple antiviral effects in most host cells, type-II IFNs play more
regulatory roles, mainly in immune cells.
Target host
molecule
Viral
determinant
Outcome Mechanism References
IRF3 function ICP0 Inhibits type-I IFN
expression
ICP0 RING finger motif inhibits
IRF3-mediated transcription of interferon
stimulating genes
[90, 91]
Us3 Decreases IFN-β
production
Viral Ser/Thr kinase activity
hyperphosphorylates IRF3, blocking its
dimerization and nuclear translocation
[92]
UL36 Inhibits IFN-β
transcription
UL36 de-ubiquitinates TRAF3, which inhibits
stimuli-induced dimerization of IRF3
[94]
IRF3, NF-kB VP16 Inhibits IFN-β
expression
Inhibits NF-kB activation and blocks the
recruitment of IRF3 co-activator CBP
[93]
STAT-1
function
ICP27 Neutralizes
expression of IFN-I
Interferes with nuclear accumulation of
STAT-1, impairing with the activity of this
transcription factor
[96]
STAT-2
function
Undetermined,
vhs (partially)
Interferes with IFN-I
signaling
Partially attributed to vhs-mediated
reduction of transcription factor activity
[97, 98]
Jak-1
function
Undetermined,
vhs (partially)
Interferes with IFN-I
signaling
Partially attributed to vhs-mediated
reduction of transcription factor activity
[97, 98]
IFN-ε, IFN-α Undetermined Reduces viral
dissemination and
reactivation
Activates TLR signaling through unknown
viral agonist
[99–102]
IL-29
function
Undetermined Induces IFN-β
expression. Prevents
keratinocyte and neural
infection
Unknown viral antigen activation of
TLR3 and Jak-STAT signaling
[104]
IL-28A
function
Undetermined Prevents neural
infection
Unknown viral antigen. TLR-mediated
activation of IRF7
[105]
IRF3 (interferon regulatory factor 3); NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells); STAT-1, -2
(signal transducer and activator of transcription-1, -2); Jak-1 (Janus kinase 1); IFN-ε, IFN-α (interferon-epsilon, -alpha);
IL-28A, -29 (interleukin-28A, -29); UL36 (long unique region 36); VP16 (viral protein 16); ICP27 (infected cell protein
27); TRAF3 (TNF receptor-associated factor 3); CBP (CREB-binding protein).
Table 2. HSV interference with host intracellular signaling.
HSVs encode numerous virulence factors that negatively modulate the induction of host
interferon responses and their effects, some of which were briefly discussed above (Table 2).
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For instance, HSVs interfere with PRR-mediated intracellular signaling events that otherwise
would lead to the transcription of IFN-I. Such effect has been reported to be mediated by HSV
proteins such as ICP0, which interferes with IRF3 to block the transcription of target genes,
namely, type-I IFNs [90, 91]. On the other hand, the HSV Ser/Thr kinase US3 has also been
shown to interfere with signaling mediated by this transcription factor by carrying out its
hyperphosphorylation, which blocks its dimerization, nuclear translocation, and hampers
IFN-β production [92]. Additionally, the tegument protein VP16 has also been described to
abrogate IFN-β expression by inhibiting IRF3 and NF-kB activation, specifically by impairing
the recruitment of the coactivator CBP (CREB binding protein) and not necessarily through a
mechanism that affects IRF3 dimerization, nuclear translocation, or its DNA binding activity
[93]. Finally, IFN-β transcription has also been reported to be inhibited by the viral ubiquitin-
specific protease UL36, which de-ubiquitinates TRAF3 (TNF receptor-associated factor-3) and
consequently inhibits stimuli-induced IRF3 dimerization [94]. Interference with signaling
events that lead to type-I IFN secretion has also been evidenced in vivo by the observation that
only reduced amounts of IFN-α and IFN-β are produced in the genital tract after HSV infection
[90, 95]. Negative modulation of the interferon pathway is summarized in Table 2.
Although small amounts of type-I IFNs are produced during HSV infection, the effects of these
meager amounts of interferons are neutralized by HSVs, thanks to the activity of the viral
protein ICP27, which interferes with STAT signaling (signal transducer and activator of
transcription), which is located downstream of IFN-I receptors. Indeed, HSV ICP27 interfere
with nuclear accumulation of STAT-1 and impair the function of this transcription factor [96].
Additionally, other transducers of IFN-I signaling, such as STAT-2 and JAK1 (Janus Kinase),
have also been reported to be reduced in HSV-infected cells and experiments with mutant
viruses suggest that these effects would be mediated, at least partially by virally encoded vhs
[97]. Additional viral and nonviral determinants released by HSV-infected cells have been
suggested to interfere with IFN-I signaling, although their nature has not been fully charac‐
terized [98]. Although IFN-ε signals through similar receptors than IFN-α and IFN-β, this
recently described mediator is constitutively expressed by epithelial cells in the genitalia and
would likely play a role against HSV burden [99–101]. However, the mechanism by which
IFN-ε would limit HSV infection remains to be determined. Consistent with an important role
for type-I IFNs in response to HSV infection, treatments with TLR agonists, such as imiquimod,
poly(I:C), or CpG-ODNs, discussed above all induce strong interferon responses [51, 52, 58–
61, 73]. Additionally, application of topical IFN-α has been shown to significantly reduce viral
dissemination, as well as the frequency of viral recurrences in HSV-infected patients that
manifest frequent genital viral reactivations [102]. The role of IFN-I in HSV infection is also
evidenced in experiments assessing mice that lack the receptor for this molecule (IFNAR1 and
IFNAR2c), which were inoculated in the footpads with the virus. These animals displayed
reduced HSV control and systemic infection that affected multiple organs, although the disease
was nonlethal [103].
At present, several studies seem to have identified a favorable role for type-II IFNs in HSV
infection, as discussed in the following sections. Yet surprisingly, one study that evaluated
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infection in mice that had the IFN-II receptor deleted (IFNGR1 and IFNGR2) showed that these
animals had comparable levels of virus than wild-type controls [103].
Unlike type-I IFNs, relatively few reports have documented a role for type-III IFNs in HSV
infection. One such study has reported that IFN-λ1 (IL-29) induces the expression of several
antiviral proteins in human keratinocytes. Furthermore, administration of this cytokine,
previous to HSV infection induced IFN-β and prevented keratinocyte infection upon HSV
challenge. Notably, the effect of this interferon depended on TLR3 expression, which was
upregulated, and JAK-STAT activation [104]. Additionally, IFN-λ1 and IFN-λ2 (IL-28A) have
also been reported to suppress HSV infection in human neurons (Table 2). Again, IFN-III was
shown to induce TLR expression and elicit TLR-mediated antiviral pathways that involved
IRF7 [105]. Noteworthy, the secretion of type-III IFNs in the vaginal mucosa has been suggested
to be mainly mediated by DCs, although this has not been evaluated yet in the context of an
HSV infection [106].
Taken together, HSVs have evolved multiple mechanisms to interfere with host interferon
responses, from IFN transcription to IFN signaling. These evasion mechanisms, largely
redundant, highlight the importance of this type of response in limiting HSV infection. Indeed,
novel therapeutic strategies seem to share in common the induction of type-I IFNs, which
should facilitate the identification of novel formulations that provide beneficial effects against
these viruses.
2.3. HSV modulation of cell viability
Viruses utilize cells as substrates for replication and require, within others their translation
machinery for synthesizing their proteins. Maximization of virion production is favored by
extended cell survival and thus viruses have evolved molecular mechanisms to inhibit cell
apoptosis. As discussed above, interference with programed cell death is achieved in part by
the blockage of virus detection, but also thanks to viral determinants that directly hamper this
cellular antiviral function. Cellular apoptosis can be mediated by two major pathways
triggered either by intrinsic or extrinsic stimuli [107]. While the intrinsic pathway can be
initiated by intracellular events that alter the redox state of the cells, damage the host DNA,
or compromise mitochondrial integrity, within others, the extrinsic pathway can be elicited by
the engagement of surface receptors, such as Fas [107]. HSVs have evolved molecular deter‐
minants that block both, intrinsic and extrinsic apoptosis signaling pathways in infected cells
(Table 3). For instance, inhibition of apoptosis has been described to be mediated by the viral
proteins US3, US5, and US12, each with unique inhibitory effects over the viability of the infected
cells, either confronted or not to cytotoxic T cells [108]. More specifically, the HSV protein US3
has recently been described to mediate its antiapoptotic effects in epithelial cells, by interacting
with programmed cell death protein 4 (PDCD4) and retaining it within the nucleus of infected
cells [109]. HSV ICP10PK and UL14 would also harbor antiapoptotic effects in neurons and
epithelial cells, although the mechanisms mediating these effects remain unknown [110, 111].
On the other hand, inhibition of apoptosis in HSV-infected cells by the extrinsic pathway has
been suggested to occur by the sequestering of Fas ligand, which consequently would hamper
Fas/FasL (CD95/CD95L) engagement, and thus block the capacity of T cells to mediate the
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killing of target cells [112]. Additionally, a recent study found that although some HSV-
infected cells express Fas on their surface, HSVs can block Fas-mediated apoptosis by a
mechanism that is independent of viral activation of NF-kB, as this transcription factor could
be detected within the nucleus of infected cells [113]. Consistent with altered Fas/FasL function
in HSV-infected cells, therapeutic application of soluble Fas ligand has been reported to
ameliorate acute and recurrent herpetic stromal keratitis (HSK) in mice, by reducing inflam‐
matory infiltration into the eye and decreasing eye neovascularization in primary and
recurrent forms of HSK [114]. Interestingly, HSV glycoproteins gJ and gD have been proposed
to mediate, at least partially the inhibition of Fas-mediated apoptosis [115, 116]. Paradoxically,
gJ induces ROS within cells, which could trigger intrinsic pro-apoptotic stimuli. On the other
hand, HSVs have been recently described to be able to suppress necroptosis in human cells as
a mechanism to extend cell viability [117]. The viral proteins ICP6 and ICP10 have been recently
described as the viral determinants that block necroptosis elicited by TNF in human cells [117].
The effects of HSV determinants over cell viability are summarized in Table 3.
Cell type Viral determinant Outcome Mechanism References
Epithelial US3 Prevents apoptosis Acts retaining PDCD4
within the nucleus
[108, 109]
Fibroblast Us5 Prevents apoptosis Unclear. Inhibition of
caspase 3 activation
[108]
Fibroblast Us12 Prevents physiologic and
CTL-induced apoptosis
Unclear. Inhibition of
caspase 3 activation
[108]
Epithelial and
neuronal
ICP10PK and
UL14
Prevents apoptosis Unknown [110, 111]
Neuronal gD and gJ Prevents apoptosis Inhibits Fas-mediated pathway [115, 116]
Neuronal LAT Prevents cold shock-
induced apoptosis
Maintains high levels of
phosphorylated AKT in cells
[125]
Epithelial ICP6 and
ICP10PK
Prevents necroptosis Blocks cell death elicited by TNF [117]
Dendritic cell Undetermined Induces cell death-related
processes
Unclear [118–120]
Natural killer Undetermined Induces apoptosis Induction of Fas/FasL through infected
macrophage expression
[121]
Fibroblast ICP6 Induces necroptosis Interacts with host RIP-3 [122]
US3, 5, 12 (short unique region 3, 5, 12); ICP10PK (ICP10 serine-threonine protein kinase); UL14 (long unique region 14);
gD, gJ (glycoprotein D, J); LAT (latency-associated transcript); AKT (protein kinase B); ICP6, 10 (infected cell protein 6,
10); CTL (cytotoxic T lymphocyte); PDCD4 (programmed cell death protein 4); RIP-3 (receptor-interacting protein
kinase 3); TNF-α (tumor necrosis factor-alpha).
Table 3. HSV modulation of cell death.
Immune Evasion by Herpes Simplex Viruses
http://dx.doi.org/10.5772/64128
115
Contrarily to the observations discussed above, other studies have reported proapoptotic
effects for HSV proteins, as well as pronecrotic effects. For instance, infection of murine and
human dendritic cells with HSV induces apoptosis, but after the virus has negatively modu‐
lated some of their properties ([118–120] and below). Additionally, HSV has also been
described to induce apoptosis in natural killer cell (NK cells) upon their interaction with
infected macrophages that express Fas/FasL [121]. On the other hand, HSVs have been
described to induce necroptosis in mouse fibroblasts through the direct interaction of viral
ICP6 with host RIP3 (receptor-interacting kinase 3) [122]. Importantly, an HSV virus with ICP6
deleted was unable to produce necrosis in HSV-infected cells and RIP3-/- mice displayed
compromised control of HSV pathogenesis and replication [123].
Importantly, several reports have described that neuron infection with HSV does not lead to
cell death, but rather extends their life. Indeed, lower levels of caspase-3 transcripts have been
found in HSV-positive, rather than HSV-negative trigeminal ganglia and neurons [124].
Furthermore, HSV determinants such as the latency-associated transcript (LAT), which is
mainly expressed within infected neurons has been reported to protect cells from cold-shock-
induced apoptosis by maintaining high levels of phosphorylated protein kinase AKT within
the cells [125].
Taken together, these studies highlight unique properties of HSV in their capacity to modulate
cell viability in a cell-specific manner. While the viability of nonimmune cells that serve as a
substrate for virus replication is extended by antiapoptotic viral determinants, immune cells
are targeted for death in such a way to evade the immune system. Noteworthy, neurons which
act as reservoirs for the virus are maintained viable during infection.
2.4. Soluble mediators secreted shortly after HSV infection
Despite the capacity of HSV to limit the cell’s capacity to sense viral components or transduce
activating signals after virus detection, which otherwise could lead to optimal antiviral
responses, cells infected with HSV nevertheless secrete numerous cytokines upon infection.
Secretion of these cytokines might be promoted by host sensors that effectively detect HSV
determinants or alternatively might result from virus-oriented immune modulation intended
to promote infection and persistence [32]. Thus, to date it is unclear whether soluble mediators
secreted by HSV-infected cells either contributes to virus control and spread or promotes the
virus’ life cycle within the host.
Signaling events that lead to the secretion of soluble mediators after microbe or danger signal
detection is frequently mediated by the nuclear factor NF-kB, which translocates from the
cytoplasm to the nucleus to promote gene transcription [126]. Because of the importance of
NF-kB in this process, HSV encode several determinants to dampen the activity of this
transcription factor. For instance, the HSV US3 kinase has been reported to hyperphosphorylate
NF-kB (p65) and impairs its translocation to the nucleus, interfering with IL-8 secretion [127].
On the other hand, the HSV UL42 protein, which encodes for a DNA polymerase processivity
factor, also binds to p65/RelA and to p50/NF-kB1 (NF-kB1 forms) to negatively modulate their
migration into the nucleus after stimulation with TNF-α [128]. HSV ICP0 has also been
described to inhibit NF-kB activation mediated by TNF-α, by interacting similarly with p65/
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RelA and p50/NF-kB1 [129]. HSV VP16 similarly has been shown to interfere with NF-kB
activation in human endothelial kidney cells [93]. Paradoxically, other studies have proposed
that HSV infection can induce persistent NF-kB nuclear translocation, although without
concomitant transactivation activity and in epithelial cells from the retina (retinoblastoma)
[130, 131]. Importantly, blocking NF-kB nuclear translocation in these cells significantly
reduced virus yield. Altogether, these studies demonstrate significant modulation of this
important transcription factor by HSV determinants, which may result in different cellular
outcomes depending on the cell type infected.
Although HSV negatively modulates NF-kB activation, HSV-infected cells can produce
numerous soluble mediators. For instance, primary endometrial genital epithelial cells infected
with HSV produce CCL2, IL-8, IL-6, and TNF-α [132]. On the other hand, samples from the
cervical mucus of women infected with HSV show elevated amounts of CXCL9 [133]. The latter
chemokine together with CXCL10 have been shown to participate in antiviral responses
against HSV in CNS infection in the mouse model by recruiting NK and cytotoxic T cells to
the infected tissue [134]. Other chemokines, such as CCL2, which are promoted by HSV
infection, may play positive roles against the virus in ocular infection, as shown in mice; CCL2
knockout mice displayed significant viral infection and reduced inflammatory monocyte
recruitment into the affected tissue [135]. On the contrary, blocking specific chemokines such
as CXCL2 which is released by monocytes in response to HSV is thought to bring neutrophils
into the infection site, which would promote unwanted damaging responses to the host,
particularly neurons [136].
HSV also induces IL-6 in numerous cell types after infection, such as microglia, mast cells, and
dendritic cells. Importantly, this cytokine shows protective effects in microglia, which seems
to be mediated by STAT3; however, the details of the processes that converge toward its
protective effects remain unresolved [137, 138]. Mast cells secrete IL-6 early after HSV infection,
as well as TNF-α. Interestingly, these soluble mediators are not promoted by HSV directly in
this case, but by soluble molecules secreted by keratinocytes infected with HSV [139]. Impor‐
tantly, animals that lack IL-6 or TNF-α succumb to death after HSV infection, which indicates
that these soluble molecules play positive antiviral effects for the host [139]. Nevertheless, other
studies propose that this latter cytokine might play a negative role for the host, as treating
animals with an anti-TNF-α antibody in combination with the antiviral valacyclovir signifi‐
cantly ameliorated the prognosis of HSV encephalitis [140]. On the other hand, before DCs are
killed by HSV, these cells secrete IL-6 and numerous other cytokines [119].
Noteworthy, HSV has also been described to induce the secretion of cytokines and chemokines
that could favor host infection by other sexually transmitted microbes, such as the human
immunodeficiency virus [141]. Accumulating evidence indicates that infection with HSV-2 can
increase host susceptibility up to fourfold to acquiring HIV [142–145]. Additionally, coinfection
with these pathogens augments the shedding of both viruses, likely worsening patient
prognosis. Importantly, similar findings have been observed in the mouse model with
HIV/HSV coinfections [146]. Such increase in the susceptibility of acquiring HIV in HSV-
infected individuals would be mediated by numerous factors, such as the increased recruit‐
ment, to the infection site of cells that are targeted by HIV [147–149]. Furthermore, cells infected
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with HSV secrete cytokines that reactivate latent HIV from infected cells [119, 150] and may
augment the expression of surface ligands that promote HIV infection [151, 152]. Finally, HSV
infection can downmodulate the expression of molecules that favor the neutralization and
destruction of HIV [153].
A soluble mediator frequently associated with virus control and clearance is IFN-γ. This innate
and adaptive immune cytokine is recurrently associated with increased protection against
HSV in numerous HSV infection models and considered an important mediator in the
mechanism of action of different prophylactic formulations [154–157]. Importantly, in the
absence of IFN-γ, T cells directed against HSV secrete alternative cytokines that are known to
possess antiviral functions, yet they are not protective against genital infection [158]. Thus,
IFN-γ seemingly plays an important role in eliciting protective immunity against HSV.
Taken together, HSVs elicit the secretion of cytokines and chemokines both by immune and
nonimmune cells. Yet, whether these soluble mediators play favorable roles for the host or
these viruses remains somewhat unknown and requires further examination. To date, only
type-I IFNs and IFN-γ seem to play evident favorable roles against HSV.
3. Herpes simplex viruses interfere with innate immunity
3.1. Interference with complement function
Complement is an acellular component of innate immunity that recognizes foreign elements
and subsequently undergoes a series of controlled molecular chain reactions that either
culminate with the establishment of a protein pore-forming complex that attacks bilipid
membranes or induce receptor-mediated engulfment by cells [159]. Importantly, formation of
the pore complex can be promoted either directly by the recognition of microbial molecular
patterns on the surface of the virus by complement components, or induced by the Fc portion
of antibodies that bind to foreign elements.
To counteract the effect of the complement, HSVs utilize glycoprotein gC, which binds to C3b
and blocks its activity by impairing antibody-induced complement activation (Table 4) [160,
161]. Inhibition of C3 impairs complement-mediated virus inactivation and the lysis of virus-
infected cells. Furthermore, gC also binds to complement component C5 to block its down‐
stream activities, such as immune cell chemoattraction and membrane attack complex
formation (Table 4) [162, 163].
HSVs have also evolved molecular determinants that bind to complement components
required for antibody-mediated complement activation, as discussed below. Thus, by
interfering with complement components HSVs increase their viability in the mucosae and
sera of infected patients, which favors the infection of target cells.
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Innate immune
process altered
Viral
determinant
Outcome Mechanism References
Complement gC Inhibits antibody-mediated
complement activation
Acts as a receptor for complement
component C3b
[160, 161]
Complement gC Impairs chemoattraction and
membrane attack complex
formation
Binds to complement component C5
hampering its catalytic activity and
inhibiting downstream events
[162, 163]
Natural killer gD Suppresses NK degranulation
and cell-mediated lysis of
infected cells
CD112 downregulation leading to
reduced DNAM-1 activity
[168]
Natural killer Undetermined Decreases NK activation Reduces the surface expression of
MICA, ULBP1, ULBP2 and ULBP3
[169–171]
Natural killer Undetermined Induces cell apoptosis Induces Fas/FasL interactions
through infected macrophages
[121]
Natural killer T
cells
US3 Inhibition of antigen
presentation to NKT cells
Phosphorylation of KIF3A produces
CD1d downregulation in infected
cells
[175–177]
gC, gD (glycoprotein C, D); US3 (short unique region 3); C3b, C5 (complement component 3b, 5); NK (natural killer
cell); CD112 (nectin-2); DNAM-1 (DNAX accessory molecule-1); MICA (MHC class I polypeptide-related sequence A);
ULBP1, 2, and 3 (UL16 binding protein 1, 2 and 3); KIF3A (kinesin family member 3); CD1d (antigen-presenting
glycoprotein CD1d).
Table 4. Evasion of innate immunity.
3.2. Negative modulation of NK and NKT function
Besides complement, innate immunity is also composed of numerous cells, such as macro‐
phages, neutrophils, mast cells, basophils, eosinophils, and innate lymphoid cells (ILCs),
within others. Importantly, HSV modulates the function of some of these cells, notably NK
(Table 4). NK cells usually play important roles in eliminating infected cells that have lost class
I major histocompatibility complex molecules (MHC-I) on their surface, because of microbe
interference. Although NK cells can directly sense HSV through TLR2 and have been reported
to be activated by plasmacytoid dendritic cells that have contacted HSV, their function is
nevertheless dampened by the virus [164–167]. Indeed, gD has been shown to suppress
DNAM-1-dependent NK-cell-mediated lysis of HSV-infected cells [168]. Furthermore, HSVs
can dampen the surface expression of the NK-activating ligand MICA (MHC class I polypep‐
tide-related sequence A) in infected cells, by retaining this molecule intracellularly [169, 170].
More recent studies have revealed that HSV can also interfere with the expression of additional
NK-activating ligands, such as ULBP1, ULBP2, and ULBP3 [171]. Importantly, HSVs can
induce apoptosis in NK cells through Fas/FasL interaction between NK cells and HSV-infected
macrophages, thus eliciting their deletion upon infection [121]. Although there is abundant
evidence for negative modulation of NK cells by HSV, the contribution of these cells to HSV
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pathology remains somewhat controversial as both, negative and positive roles have been
described for this cell population during HSV infection [172, 173].
Another innate immune cell type directly affected by HSV is natural killer T cells (NKT cells)
(Table 4). These cells recognize glycolipid antigens presented on CD1d molecules [174].
Importantly, cells infected with HSV display reduced expression of CD1d on their surface, as
they are redirected by viral determinants to intracellular compartments [175, 176]. Redirection
of CD1d from the cell surface is mediated by the phosphorylation of host KIF3A by the viral
kinase US3 [177]. Interestingly, vaginal application of α-galactosyl-ceramide an NKT ligand is
shown to activate and recruit NKT cells to the genital tissue and decrease the susceptibility to
HSV infection [178]. Remarkably, a recent report showed that NKT cells can contribute at
determining the magnitude and profile of HSV-specific IgG antibodies upon HSV infection.
HSV-infected NKT-cell-deficient mice displayed reduced amounts of antiviral IgM and IgG
antibodies, as compared to wild-type mice [179]. These results suggest that NKT cells play an
important role against HSV and that these viruses have evolved molecular mechanisms to
interfere with their function. Furthermore, activating NKT cells with glycolipids may serve as
a strategy to promote robust antibody responses against these viruses.
3.3. HSV interfere with dendritic cell function
Dendritic cells are immune cells strategically positioned at the interphase of innate and
adaptive immunity. They are specialized in sensing microbes and danger signals, and also in
integrating these signals and transducing them onto other cells for modulating the immune
response to antigens [180–183]. Because DCs are key at connecting innate and adaptive
immunity and clearing microbes, pathogens have evolved numerous immune evasion
mechanisms to overcome their function [181, 184–189]. Importantly, HSV has been shown to
infect DCs and to modulate their function by altering their maturation and capacity to activate
T cells (Table 5) [118, 119, 190]. Furthermore, HSV can negatively modulate the
autophagosome within DCs and interfere with their antigen processing capacity. This process
is mediated by the viral protein γ34.5, which blocks autophagosome maturation [191, 192]. On
the other hand, HSV-2 protein ICP47 has been shown to specifically block the expression of
particular alleles of MHC-I on the surface of human DCs, namely, HLA-C, potentially
rendering these cells more susceptible to NK killing and reducing the spectrum of HSV-
derived antigens presented by these cells [193]. Remarkably, HSV has been shown to suppress
many functions of DCs via caveolin-1 (Cav-1) by studying these cells in the lungs. HSV-
induced Cav-1 was shown to downregulate the expression of inducible nitric oxide synthase;
indeed, Cav-1-deficient mice or enhancement of nitric oxide production in wild-type mice
ameliorated virus elimination and reduced pathology after HSV infection [194]. Furthermore,
such crosstalk may occur between nonvirally infected dermal dendritic cells phagocytizing
HSV-infected epidermal Langerhans cells, which are the first dendritic cells to encounter HSV
in the skin [195].
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Adaptive
immune cell
affected
Viral determinant Outcome Mechanism References
Dendritic cell Undetermined Altered DC maturation and
capacity to activate T cells
Undetermined [118, 119, 190]
Dendritic cell γ34.5 Interference with autophagosome
function and hence antigen
processing
Blocks autophagosome
maturation
[191, 192]
Dendritic cell ICP47 Increased susceptibility to NK
attack
Blocks MCH expression
(HLA-C allele)
[193]
Dendritic cell HSV-induced
Cav-1
Reduced virus elimination and
increased pathology
Downregulates the
expression of inducible nitric
oxide synthase
[194]
Dendritic cell Undetermined Induces DC cell death Undetermined [118–120]
Humoral gE Blocks antibody function
related to complement activation
and
antigen phagocytosis
Binding to the Fc portion of
antibodies. Competes
with C1q and FcγRs
[201, 202]
T cell ICP47 and US3 Reduced CTL recognition of
infected cells and decreased
naïve T cell activation
Interferes with host
TAP protein, impairing
peptide-MHC complex
presentation
[205, 206]
T cell gD, gB, gH, gI,
and gL
Reduction in T cell activation and
function. Decreases IL-2 secretion
Signals through HVEM. Alters
CD3-dependent intracellular
calcium signaling
[208]
T cell US3 Impairs T-cell activation Interferes with TCR signaling.
Blocks TRAF6 activity, altering
LAT function
[209]
T cell gD Promotes Treg cell function with
increased IL-10 secretion.
Likely to alter CTL activity
Induces proliferation of T CD4+
FoxP3+(CD25+) cell subsets
[213–217]
γ34.5 (late gene gamma 34.5, ICP34.5); ICP47 (infected cell protein 47); Cav-1 (caveolin-1); gB, gD, gE, gH, gI, gL
(glycoproteins B, D, E, H, I, L); US3 (short unique region 3); DC (dendritic cell); NK (natural killer cell); Treg
(regulatory T cell); MHC (major histocompatibility complex); HLA-C (human major histocompatibility complex chain
C); C1q (subcomponent of the C1 complex of the classical pathway of complement activation); FcγR (Fc gamma
receptor); TAP (transporter associated with antigen processing); HVEM (herpesvirus entry mediator); IL-2 (interleukin
2); CD3 (cluster of differentiation 3); TCR (T-cell receptor); TRAF3 (TNF receptor-associated factor 3); LAT1 (linker for
activation of T cells); FoxP3 (forkhead box P3 protein).
Table 5. Evasion of adaptive immunity.
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Importantly, experiments with animals depleted of DCs have shown that these cells are
involved in neuron infection, as up to fivefold less latent virus can be found in the trigeminal
ganglia of animals devoid of these cells [196]. Consistent with this notion, another study found
that depletion of CD11c+ CD8α+ DCs reduced HSV latency in neurons after ocular infection
and that Flt3L treatment, which increases the number of DCs in the tissues, enhanced virus
infection of neurons [197]. These studies suggest that DCs may be used as Trojan horses by
HSV to reach neurons or that the virus might manipulate these cells in such a way to gain
access to the former. However, another study that assessed HSV infection through the footpad
in the mouse model found that depletion of DCs was associated with increased viral loads in
neurons [198].
Taken together, these studies evidence numerous evasion strategies evolved by HSV to alter
the function of DCs and consequently innate and adaptive immunity (discussed below).
Additionally, these viruses seem to have harnessed the mobile properties of DCs to spread
onto other host cells and tissues, namely, neurons. The fact that HSVs ultimately induce DC
apoptosis will likely interrupt the establishment of effective and robust immune responses
against these viruses.
4. Herpes simplex viruses evade adaptive immunity
4.1. Interference with humoral immunity
Although natural infection with HSV elicits antiviral antibodies with in vitro neutralizing
capacities, these responses seem largely insufficient in most individuals when it comes to limit
HSV symptoms and virus shedding. This host antibody response is mostly directed to few
surface viral antigens, mainly gD, gB, and, to a lesser extent, gC all of which are essential for
virus entry, except for gC in HSV-2 [199]. For antibodies to exert effective antiviral activities
they need not to be necessarily neutralizing, as antibodies can also elicit complement activation
and immune complex-induced phagocytosis, thanks to their Fc portion [200]. However, HSVs
have evolved molecular mechanisms to evade these antibody functions (Table 5). Notably, the
HSV-encoded glycoprotein E (gE) can interfere with complement activation by directly
binding to the Fc portion of antibodies and competing with complement component C1q [201,
202]. Indeed, gE functions as an IgG Fc receptor (FcγR) that binds the Fc domain of IgG
antibodies and thus blocks their capacity to promote complement activation, altogether
impeding phagocytosis by immune cells [202–204]. Importantly, specific interference with
anti-HSV antibodies and not other circulating antibodies is achieved, thanks to the relatively
low affinity of gE for the Fc portion of antibodies; antibodies are stabilized on the virus surface
only if the Fab portion of the antibody is also bound to a viral antigen by its antigen-binding
region. Hence, HSV has evolved molecular determinants to persist within the host and shed
onto others, despite the existence of virus-neutralizing antibodies. Such evasion mechanisms
have led to difficulties in the development of prophylactic formulations against HSV, and is
further discussed below.
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4.2. Evasion of T cell immunity
T cells can recognize microbe-derived protein fragments presented on the surface of infected
cells and destroy these cells to limit virus replication and shedding onto other tissues and
organisms. However, HSV encode molecular determinants that interfere with viral antigen
presentation to T cells, namely, with MHC-I presentation, and thus the virus can hamper T-
cell recognition of infected cells. HSVs interfere with the presentation of viral antigens by
blocking the function of host TAP protein (transporter associated with antigen processing),
which translocates self- and foreign peptides from the cytoplasm into the rough endoplasmatic
reticulum for peptide loading onto MHC-I molecules (Table 5); TAP inhibition is mediated by
the HSV protein ICP47 [205] and the US3 kinase [206]. Reduced peptide/MHC (pMHC)
complexes on the surface of infected cells dramatically reduces the chances of cytotoxic T cells
detecting HSV-infected cells, as well as the capacity of HSV-infected professional antigen
presenting cells to activate naïve T cells.
Furthermore, additional mechanisms exist by which HSVs can negatively modulate the
activation and proliferation of T cells (Table 5). For instance, the viral glycoprotein D binds to
HVEM (herpesvirus entry mediator) on the surface of immune cells, which is a receptor
belonging to the TNF-receptor superfamily and whose intracellular signaling mechanisms
depends within others on the engagement of its different ligands and their orientation (cis vs.
trans) [207]. gD binding to the cell surface of T cells has shown to alter calcium signaling within
T cells after CD3 engagement, likely by interfering with the capacity of T-cell receptor to
appropriately transduce intracellular signals that lead to suitable activation and function of
these cells [208]. For instance, Jurkat T cells cultured with HSV and an activating CD3 antibody
exhibit hampered IL-2 secretion [208]. A similar effect was observed with other HSV glyco‐
proteins, namely, gB, gH, gI, and gL in the same study [208]. A recent report suggests that
impaired T-cell activation would also be mediated by HSV Us3 protein interference with T-cell
receptor signaling, specifically by altering linker for activation of T cells (LAT1) within these
cells [209]. Importantly, infection of T cells (other than Jurkat cells) requires the presence of
antigen-presenting cells for efficient virus transfer, a process termed virological synapse.
Indeed, primary cultures of T cells incubated with HSV alone are only infected at very low
frequencies, while adding fibroblasts significantly enhances the formation of virological
synapses that culminate in a substantial increase in the number of T cells infected with these
viruses [210]. Importantly, HSV has been described to lead to T-cell apoptosis [211].
T cells can carry out numerous functions depending on their phenotype. While cytotoxic T
cells are specialized in killing microbe-infected cells, regulatory T cells (Tregs) are specialized
within others in controlling the magnitude of the immune response to antigens [212]. In this
regard, HSV seems to promote the proliferation of regulatory T cells through the binding of
gD to HVEM receptors on the cell surface to promote the secretion of signature cytokines
attributed to these cells, such as IL-10 (Table 5) [213–216]. The promotion of Tregs might alter
the activity of cytotoxic T cells intended to control the virus [213, 217]. Consistent with a
negative role for Tregs in HSV infection, protection elicited against this virus in an animal
model with previous immunization correlates with relatively low numbers of Tregs [218].
Nevertheless, another study proposes that deletion of Tregs in HSV-infected animals interferes
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with the migration of immune cells to the site of infection, negatively affecting the survival of
infected animals [219]. Thus, further studies are needed to determine the contribution of Tregs
in HSV infection.
4.3. Past and present vaccine attempts
Availability of an effective vaccine against HSV would be an important public health advance,
mainly because individuals with genital herpes display increased susceptibility to acquire HIV
[141–145]. Importantly, previous efforts invested on the development of vaccines against HSV
have concentrated on subunit approaches consisting mainly on one viral glycoprotein, namely,
gD (Table 6) ([220], http://clinicaltrials.gov). Glycoprotein gD is conserved within HSV
serotypes and plays a key role during cell infection [221]. Furthermore, this viral protein
harbors epitopes for CD4+ T cells [222], CD8+ T cells [223], and neutralizing antibodies [224]
and is immunodominant as evidenced by clinical data showing that the majority of HSV-
infected individuals have neutralizing antibodies against this protein [199]. Regretfully, this
insisted strategy, which combines gD with adjuvants, recently failed in a phase 3 clinical trial;
indeed, the formulation failed at reducing both HSV-2 infection and minimizing the shedding
of the virus [225, 226]. Remarkably, the formulation tested in this and previous clinical trials
induced anti-gD neutralizing antibodies in the vaccinated, as well as T CD4+ cells [220, 227–
230]. However, the magnitude of these responses may have been too weak for significant
protection against HSV-2 after exposure [199, 228, 231, 232]. Unexpectedly, the vaccine
provided 35% cross-protection against HSV-1 infection and 58% cross-protection against
HSV-1 disease [227]. An important concern that arose from these results was whether the
current animal models used to assess the efficacy of new HSV vaccines satisfactorily recapit‐
ulate what occurs in humans. It is also unclear whether the amount and/or quality of neutral‐
izing antibodies elicited against HSV and T cells produced by vaccine formulations, such as
the glycoprotein D/AS04 vaccine, play any relevant role in protection against HSV-2; further‐
more, whether previously considered correlates of protection as anti-gD antibodies play any
relevant role against this virus.
Importantly, a recent study suggests that anti-HSV antibodies, different from those directed
against gD, might account for effective protection against HSV-2 after immunization with a
discontinuous virus (Table 6). Indeed, animals immunized subcutaneously with a genotypi‐
cally deleted gD virus elicited remarkable protection against genital and skin challenge with
HSV-1 and HSV-2, which was mediated by antibodies. Noteworthy, the antibodies elicited by
this attenuated HSV strain were poorly neutralizing and were mainly directed against gB [233].
A somewhat similar result was found in another study with an 0ΔNLS-attenuated HSV strain,
which elicits antibodies against numerous virus-infected cell proteins (ICP) and gB, within
others (Table 6) [234–236]. Other attenuated HSV strains have also provided promising results
in numerous mouse models and should move onto clinical trials, such as the HSV-2 dl5-29
strain, which has UL5 and UL29 deleted from its genome (Table 6) [237–239]. Additional
attenuated viral strains that confer significant protection against viral challenge are HSV
strains that are impaired at infecting neurons, such as a gD mutant virus [240], HSV deleted
at UL39 (ICP10ΔPK) [241], and HSV deleted at gE (Table 6) [242]. Regretfully, an HSV strain
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deleted at gH, which showed early promising results in animal models, was later shown to be
ineffective in humans in a clinical trial [243]. Although most of these strategies elicit both anti-
HSV antibodies and antiviral T cells, the main immune components involved in protection
against HSV challenge remain unknown. Importantly, a recent study suggests that other
animal models different from the guinea pig and the mouse infection model might be better
suited for testing anti-HSV vaccine formulations. For instance, the cotton rat Sigmodon
hispidus parallels well the results obtained with the D/AS04 vaccine in humans, both for HSV-1
and HSV-2 [244].
Formulation type Outcome Development stage References
Subunit protein gD plus adjuvant Alum
and MPL (gD/AS04) 
Induces T CD4+ and antibody
response. No clinical protection for
shedding
and infection. 
Clinical phase 3
(completed) 
[199, 220, 225–
233] 
Live attenuated, HSV-2 virus
with gH deletion (HSV-2 ΔgH) 
Safe and immunogenic, yet did not
confer protection to HSV infection. 
Clinical phase 2
(completed) 
[243] 
Live attenuated, HSV-2 virus
with UL39 deletion (ICP10ΔPK) 
Induction of Th1 immunity  Clinical phase 2
(completed) 
[241] 
Live attenuated, HSV-2 virus with
UL5 and UL29 deletions (ACAM529) 
Reduced disease, shedding,
seroconversion, and latency 
Preclinical stage  [237–239] 
Live attenuated HSV-2 virus with
gD mutation (HSV-2-gD27) 
Protects from challenge and reduces
viral load in neurons 
Preclinical stage  [240] 
Live attenuated HSV-2 virus
with gD deletion (HSV-2 ΔgD−/+) 
Protects from genital and skin
challenge and blocks neuronal
infection. Antibody-mediated
protection 
Preclinical stage  [233] 
Live attenuated, HSV-2 virus
with gE deletion (HSV-2 ΔgE2) 
Reduced infection and recurrence  Preclinical stage  [242] 
Live attenuated HSV- 2 virus
with ICP0 deletion (0ΔNLS) 
Antibody response against gB
and ICP viral proteins 
Preclinical stage  [234–236] 
AS04 (adjuvant system 04); MPL (monophosphoryl lipid A); gD, gE, gH (glycoprotein D, E, H); ICP10ΔPK (infected
cell protein 10 lacking the PK domain); Th1 (T helper-1); UL5, UL29, UL39 (short unique region 5, 29, and 39); ICP0
(infected cell protein 0).
Table 6. Past and present vaccine attempts against HSV.
On the contrary to the evidence that suggests a role for antibodies in protection against HSV
infection, a recent study proposes that effective protection against ocular HSV may be achieved
by eliciting a robust T cell response alone. Indeed, humanized HLA transgenic animals
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vaccinated with T cell epitopes from different viral proteins identified in asymptomatic
individuals and combined with adjuvant was shown to confer protection against ocular herpes
[245–247]. However, whether such results relate specifically to this type of herpetic disease or
whether these T cells ultimately elicit an antibody response against HSV upon virus challenge
remains unknown. Noteworthy, an important limitation of vaccine approaches that are based
on one or few viral proteins is that only an oligoclonal set of T cells will be elicited, which may
limit the effectiveness of formulation to a narrow set of individuals [248, 249].
Taken together, the HSV vaccine field has suffered an important failure and will need to revisit
the immunobiology of its diseases. Importantly, the race for the development of novel
prophylactic formulations against these viruses is reopened. While numerous groups aim at
vaccine strategies that are based on defined viral proteins or viral epitopes, others propose
attenuated HSV strains as an alternative for eliciting multiantigenic immune responses against
these viruses. Regardless of the methods, a novel vaccine against HSV must guarantee safety
for the immunocompetent and notably immunocompromised individuals. Remarkably, the
lack of vaccines against HSV has encouraged considerable research in the field of microbicides,
which might provide a strategy to prevent infection with these viruses [4].
5. Concluding remarks
Herpes simplex viruses have proven to be masters of immune evasion as they encode numer‐
ous molecular determinants that promote evasion of host sensing, signal transduction,
cytokine secretion by immune and nonimmune cells, and, most importantly, interference with
innate and adaptive immunity. These attributes likely explain the coexistence of HSV and
humans since time immemorial and facilitates their high prevalence in the population [250].
Although HSV are seldom life threatening, the important economic burden they elicit with the
diseases they produce and their association with HIV infection calls for the implementation of
novel vaccines and improved treatments to stop their effects. Hopefully, lessons learned from
past failed clinical trials will lead to novel strategies that will ultimately limit the impact of
these viruses.
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